Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Travere rapeutics

FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).

Here's Why Travere Therapeutics Shares Are Rising Today

Here's Why Travere Therapeutics Shares Are Rising Today

Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy.

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Travere Therapeutics's Earnings: A Preview

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Travere Therapeutics will report an earnings per share (EPS) of $-0.72.

Organisations

Advanced Micro Devices

Dell Technologies

Coinbase Global

Motorsport Games

Bank of New York Mellon

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play